Treatment strategies for DNA repair-deficient prostate cancer

Benjamin A. Teply, Emmanuel S. Antonarakis

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Introduction: Common recurrent genetic alterations have been identified in prostate cancer through comprehensive sequencing efforts, and the prevalence of mutations in DNA repair pathway genes in patients with advanced and metastatic disease approaches 20–25%. Identification of these underlying DNA repair defects may present unique treatment opportunities for patients, both in terms of standard-of-care treatments and selected investigational agents. Areas covered: We review our current understanding of the genomic landscape of prostate cancer, with special attention to alterations in DNA repair pathway genes in metastatic castration-resistant disease. For patients with tumors deficient in homologous recombination repair, potential opportunities for treatment include platinum chemotherapy, poly(ADP) ribose polymerase (PARP) inhibitors, bipolar androgen therapy, and maybe immune checkpoint blockade therapy. In addition, tumors with mismatch repair defects (i.e. microsatellite instability) may be particularly susceptible to checkpoint blockade immunotherapy. Expert commentary: We anticipate that genomic profiling of tumors will become necessary to guide treatment of advanced prostate cancer in the coming years. Work is needed to define the optimal tissue to test, and to define the natural history of tumors with specific genetic defects. The prognostic and therapeutic importance of germline vs somatic DNA repair alterations, and mono-allelic vs bi-allelic inactivation, also remains unclear. Finally, optimal strategies to sequence or combine targeted agents for these patients with ‘actionable’ mutations are now needed.

Original languageEnglish (US)
Pages (from-to)889-898
Number of pages10
JournalExpert Review of Clinical Pharmacology
Volume10
Issue number8
DOIs
StatePublished - Aug 3 2017

Fingerprint

DNA Repair-Deficiency Disorders
Prostatic Neoplasms
DNA Repair
Neoplasms
Therapeutics
Recombinational DNA Repair
Microsatellite Instability
Mutation
Investigational Therapies
DNA Mismatch Repair
Castration
Proxy
Standard of Care
Platinum
Immunotherapy
Androgens
Genes
Drug Therapy

Keywords

  • PARP inhibition
  • Prostate cancer
  • homologous recombination deficiency
  • immunotherapy
  • microsatellite instability

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Treatment strategies for DNA repair-deficient prostate cancer. / Teply, Benjamin A.; Antonarakis, Emmanuel S.

In: Expert Review of Clinical Pharmacology, Vol. 10, No. 8, 03.08.2017, p. 889-898.

Research output: Contribution to journalReview article

@article{e90ece91a5be412689ee2552ead69928,
title = "Treatment strategies for DNA repair-deficient prostate cancer",
abstract = "Introduction: Common recurrent genetic alterations have been identified in prostate cancer through comprehensive sequencing efforts, and the prevalence of mutations in DNA repair pathway genes in patients with advanced and metastatic disease approaches 20–25{\%}. Identification of these underlying DNA repair defects may present unique treatment opportunities for patients, both in terms of standard-of-care treatments and selected investigational agents. Areas covered: We review our current understanding of the genomic landscape of prostate cancer, with special attention to alterations in DNA repair pathway genes in metastatic castration-resistant disease. For patients with tumors deficient in homologous recombination repair, potential opportunities for treatment include platinum chemotherapy, poly(ADP) ribose polymerase (PARP) inhibitors, bipolar androgen therapy, and maybe immune checkpoint blockade therapy. In addition, tumors with mismatch repair defects (i.e. microsatellite instability) may be particularly susceptible to checkpoint blockade immunotherapy. Expert commentary: We anticipate that genomic profiling of tumors will become necessary to guide treatment of advanced prostate cancer in the coming years. Work is needed to define the optimal tissue to test, and to define the natural history of tumors with specific genetic defects. The prognostic and therapeutic importance of germline vs somatic DNA repair alterations, and mono-allelic vs bi-allelic inactivation, also remains unclear. Finally, optimal strategies to sequence or combine targeted agents for these patients with ‘actionable’ mutations are now needed.",
keywords = "PARP inhibition, Prostate cancer, homologous recombination deficiency, immunotherapy, microsatellite instability",
author = "Teply, {Benjamin A.} and Antonarakis, {Emmanuel S.}",
year = "2017",
month = "8",
day = "3",
doi = "10.1080/17512433.2017.1338138",
language = "English (US)",
volume = "10",
pages = "889--898",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Treatment strategies for DNA repair-deficient prostate cancer

AU - Teply, Benjamin A.

AU - Antonarakis, Emmanuel S.

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Introduction: Common recurrent genetic alterations have been identified in prostate cancer through comprehensive sequencing efforts, and the prevalence of mutations in DNA repair pathway genes in patients with advanced and metastatic disease approaches 20–25%. Identification of these underlying DNA repair defects may present unique treatment opportunities for patients, both in terms of standard-of-care treatments and selected investigational agents. Areas covered: We review our current understanding of the genomic landscape of prostate cancer, with special attention to alterations in DNA repair pathway genes in metastatic castration-resistant disease. For patients with tumors deficient in homologous recombination repair, potential opportunities for treatment include platinum chemotherapy, poly(ADP) ribose polymerase (PARP) inhibitors, bipolar androgen therapy, and maybe immune checkpoint blockade therapy. In addition, tumors with mismatch repair defects (i.e. microsatellite instability) may be particularly susceptible to checkpoint blockade immunotherapy. Expert commentary: We anticipate that genomic profiling of tumors will become necessary to guide treatment of advanced prostate cancer in the coming years. Work is needed to define the optimal tissue to test, and to define the natural history of tumors with specific genetic defects. The prognostic and therapeutic importance of germline vs somatic DNA repair alterations, and mono-allelic vs bi-allelic inactivation, also remains unclear. Finally, optimal strategies to sequence or combine targeted agents for these patients with ‘actionable’ mutations are now needed.

AB - Introduction: Common recurrent genetic alterations have been identified in prostate cancer through comprehensive sequencing efforts, and the prevalence of mutations in DNA repair pathway genes in patients with advanced and metastatic disease approaches 20–25%. Identification of these underlying DNA repair defects may present unique treatment opportunities for patients, both in terms of standard-of-care treatments and selected investigational agents. Areas covered: We review our current understanding of the genomic landscape of prostate cancer, with special attention to alterations in DNA repair pathway genes in metastatic castration-resistant disease. For patients with tumors deficient in homologous recombination repair, potential opportunities for treatment include platinum chemotherapy, poly(ADP) ribose polymerase (PARP) inhibitors, bipolar androgen therapy, and maybe immune checkpoint blockade therapy. In addition, tumors with mismatch repair defects (i.e. microsatellite instability) may be particularly susceptible to checkpoint blockade immunotherapy. Expert commentary: We anticipate that genomic profiling of tumors will become necessary to guide treatment of advanced prostate cancer in the coming years. Work is needed to define the optimal tissue to test, and to define the natural history of tumors with specific genetic defects. The prognostic and therapeutic importance of germline vs somatic DNA repair alterations, and mono-allelic vs bi-allelic inactivation, also remains unclear. Finally, optimal strategies to sequence or combine targeted agents for these patients with ‘actionable’ mutations are now needed.

KW - PARP inhibition

KW - Prostate cancer

KW - homologous recombination deficiency

KW - immunotherapy

KW - microsatellite instability

UR - http://www.scopus.com/inward/record.url?scp=85025094097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025094097&partnerID=8YFLogxK

U2 - 10.1080/17512433.2017.1338138

DO - 10.1080/17512433.2017.1338138

M3 - Review article

C2 - 28573914

AN - SCOPUS:85025094097

VL - 10

SP - 889

EP - 898

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 8

ER -